JPBEONE@EC2610A

BGT Biotechnology Reports First Yearly Profit, Innovation Pharmaceuticals Reach Critical Milestone

BeiGene Announces Revenue and Net Profit for 2025

BeiGene Achieves First Annual Profit, Significant Commercial Progress

BeiGene Submits Application for Zanidatamab and BGB-A317 Combination Therapy

BeiGene's Revenue Grew by 40.2% in 2025 and Achieved Profitability

BEONE MEDICINES to Release FY2025 Earnings on March 26 During-Market (BJT), Forecast Revenue HKD 41.24 B, EPS HKD 1.9407

Sci-Tech Innovation Board Companies Projected Earnings Growth in 2025, Several Companies Expected to 'Delist'

BeiGene Reports First Profit in 2025 with Record Sales

CICC Publishes Report on Biogen's FY2022 Revenue Meeting Expectations

JPMorgan Adjusts Biogen's Target Price

BOA Raises Price Target for BeiGene and Sees Strong 2026 Prospects

BeiGene Reports 2025 Earnings, Transitions to Profitability but Sees Stock Decline

Guotai Junan and DBS Maintain Buy Rating on BeiGene

BeiGene Achieves First Yearly Profit but Faces Slowing Growth

BeiGene Reports Profit of $286 Million in 2024, Reversing Previous Losses

BeiGene Announces 2025 Financial Report with 40% Revenue Growth

BEONE MEDICINES released FY2025 Q4 earnings on February 26 During-Market (BJT), actual revenue HKD 11.66 B (forecast HKD 11.32 B), actual EPS HKD 0.3132

BeiGene Expected to Release Q4 Earnings on Feb 26

Guopharma Completes First Delivery of BeiGene's New Product

QINGDAO HLDGS

QIANHAI HEALTH

GUOXIA TECH

BITSTRAT HLDGS

KIN SHING HLDGS

AV CONCEPT HOLD

DATRONIX HOLD

HAITIAN ANTENNA

PRODUCTIVE TECH

INVESTECH HLDGS

06160

688235

BeOne Medicines Ltd has announced the nomination of ten directors for election at its 2026 AGM, including three new candidates. Four current independent directors will retire, with no disagreements cited. The company plans to reconstitute its audit and compensation committees, indicating a refreshed governance structure. The latest analyst rating for BeOne Medicines Ltd (HK:6160) is a Buy with a price target of HK$290.00. BeOne operates in the biopharmaceutical sector, focusing on innovative medicines and is listed in Hong Kong.

Tip Ranks

BEONE MEDICINES

Beigene

BeOne Medicines

BeOne Medicines Revamps Board and Committees Ahead of 2026 AGM

AMGN

513700

516930

513120

159929

588250

512010

159837

516500

IBBQ

520880

LABU

560600

588130

512290

520690

ARKG

159316

159992

Beijing Beion Pharmaceuticals Co., Ltd. (688235) released its 2025 financial report, with annual revenue of 38.225 billion, a year-on-year increase of 40.46%; net profit of 1.461 billion, an improvement compared to a net loss of 4.978 billion in the same period last year. Revenue in the fourth quarter was 10.63 billion, with a net profit of 322 million. During the reporting period, research and development expenses amounted to 15.508 billion, and the net cash flow from operating activities was 13.713 billion. Amgen and Baker Brothers are the core shareholders, holding 17.09% and 8.03% of the shares, respectively

雷帝触网

Amgen

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal 800 Health Care ETF

Penghua SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI 300 Health Care ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI Biotechnology Theme ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bear 3X

ChinaAMC CSI Biotechnology Theme ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

Ark Genomic Revolution ETF

E Fund Hang Seng SCHK Innovative Drug ETF

iShares US Pharma

iShares Biotechnology ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Baker Tech

Endra Life Sciences

Origin Life Sciences

Nano Labs

Annaly Capital Mgmt

Rand Capital

Sculptor Capital

ICBC

Bank Of Communications

BANKCOMM

ENDRA LIFE SCIENCES INC

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

BeOne Medicines annual revenue is 38.2 billion: net profit 1.46 billion, Amgen and Baker are core shareholders

STECH

00HSI

09992

01347

03067

03033

520920

36Kr learned that the Hang Seng Index rose 0.43% at midday, and the Hang Seng TECH Index rose 0.17%; the durable goods, semiconductor, and software services sectors led the gains, with POP MART rising over 6%, Baidu Group rising over 3%, and HUA HONG SEMI rising over 2%; the automotive, pharmaceutical and biotechnology, and energy sectors weakened, with Li Auto and Sinopec Oilfield Service falling over 2%, and BEONE MEDICINES falling over 1%; southbound funds had a net purchase of HKD 789 million

36Kr

Hang Seng TECH Index

Hang Seng Index

POP MART

HUA HONG SEMI

ISHARESHSTECH

CSOP HS TECH

Tianhong Hang Seng TECH ETF(QDII)

BIDU-SW

The Hang Seng Index rose 0.43% during the midday break, and the Hang Seng TECH Index increased by 0.17%

Amgen's bispecific T-cell engager tarlatamab has received regulatory approval in China, expanding its oncology portfolio into a major cancer market. The approval, announced by BeOne Medicines, is for adult patients with extensive-stage small cell lung cancer who have progressed after chemotherapy. Tarlatamab, marketed as Imdelltra in the U.S., targets specific proteins on tumor cells and T cells to enhance immune response. Clinical data shows a 46.3% objective response rate and manageable safety profile. Commercial details remain undisclosed, but analysts predict significant market potential, estimating over $2 billion in annual sales globally.

Pharmexec

<![CDATA[Amgen’s Tarlatamab Approved in China ]]>

600196

FOSUN PHARMA announced that CFO Chen Zhanyu resigned due to adjustments in work arrangements, effective April 2, 2026, and will continue to serve as Senior Vice President after resignation. Huang Zhi will take over as CFO, starting from April 2, 2026. Huang Zhi joined FOSUN PHARMA in February 2026 and has held finance-related positions at BeOne Medicines and Novartis

FOSUN PHARMA

Dacheng CSI All Share Health Care Equipment and Services ETF

FOSUN PHARMA CFO Chen Zhanyu resigns, former BeOne Medicines executive Huang Zhi takes over

BGNE

SBIO

Ahead of the upcoming American Association for Cancer Research (AACR) annual meeting and the American Society of Clinical Oncology (ASCO) annual meeting, biopharmaceutical stocks have performed well, particularly Beigene and WuXi AppTec. Beigene is expected to achieve a net profit of $287 million in 2025, with total annual revenue of $5.343 billion, a growth of 40%. Its main product, "Tislelizumab," has performed exceptionally well in the European and American markets, driving revenue growth. The company has also achieved significant income from external licensing, with innovative drug licensing deals exceeding $60 billion in the first quarter

Stheadline

WuXi AppTec

WUXI APPTEC

iShares Global Healthcare

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VG Health

Innovative drugs welcome the "going abroad" harvest period, with a surge in external licensing amounts. Beigene turns losses into profits, and WuXi AppTec sees a significant increase in orders. | Investment Pursuit

01024

00700

06862

03690

09618

09888

09696

02015

00020

As of noon, the three major indices of the Hong Kong stock market rose collectively, with the Hang Seng Index approaching the 24,993-point mark and the Hang Seng Tech Index returning above 4,811 points. Market sentiment is relatively stable, with heavyweight and tech stocks resonating upward. In terms of sectors, the restaurant and retail industries performed strongly, with Haidilao leading the midday gains at 6.47%, and core assets such as Meituan and BYD leading in trading volume. Investors are closely monitoring macroeconomic data and performance guidance from core sectors, with overall market trading remaining active

- As of March 27, 2026, Hong Kong’s stock market indices showed positive movement, with the Hang Seng Index at 24,993.64, up 0.55%.  
- Notable performances included Haidilao, which rose 6.47%, reflecting recovering demand in the restaurant sector, while macroeconomic indicators are drawing investor focus.  
- The trading volume highlighted major players, including Meituan and Tencent, with respective figures of 62.41 billion HKD and 59.09 billion HKD amid mixed sector performance.

Market Heartbeat

KUAISHOU-W

TENCENT

HAIDILAO

MEITUAN

JD-SW

TIANQI LITHIUM

LI AUTO-W

SENSETIME-W

Hong Kong Stock Midday Review | Hang Seng Index Approaches 25,000 Points, Strong Performance in Dining Retail with Haidilao Up 6.47%

BeiGene's total revenue for 2025 increased by 40.2% year-on-year, with net product sales amounting to $5.282 billion, up 39.8% year-on-year. Sales of its core product, Brukinsa, reached $3.928 billion globally, a year-on-year increase of 48.6%, maintaining its leading global position among BTK inhibitors. Tislelizumab sales were $737 million, up 18.8% year-on-year

- BeiGene achieved a milestone in 2025 with a net profit of $287 million, reversing a loss of $645 million from the previous year.  
- Total revenue reached $5.343 billion, a 40.2% increase, driven by strong sales of core products and improved cash flow, totaling $4.548 billion by year-end.  
- The company also made significant progress with its pipeline, gaining FDA priority review for a new treatment for blood cancers and advancing its product offerings in solid tumors.

Wallstreetcn

Achieves Annual Profitability for the First Time! BeiGene Reports 2025 Net Profit of $287 Million, Revenue Surges 40% to $5.34 Billion | Earnings Watch

BEONE MEDICINES expects revenue of USD 5.343 billion in 2025, a year-on-year increase of 40.2%; net profit is expected to be USD 287 million, compared to a net loss of USD 645 million in the same period last year. Risk warning: The market has risks, and investment should be cautious. This article does not constitute personal investment advice

华尔街见闻资讯

Beijing Beone Medicines: Revenue of USD 5.343 billion in 2025, a year-on-year increase of 40.2%; net profit of USD 287 million, compared to a net loss of USD 645 million in the same period last year

BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors

BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors

BeOne Medicines Ltd has reported the results of its Fifth Amended and Restated 2018 Employee Share Purchase Plan, where 4,431 employees purchased 57,023 ADSs at a 15% discount. This represents about 0.05% of the company's issued capital. The plan aims to enhance employee ownership without significant dilution, with 2,438,481 shares available for future grants. The latest analyst rating for BeOne Medicines (HK:6160) is a Hold with a price target of HK$200.00. The company operates in the biopharmaceutical sector and is listed in Hong Kong.

BeOne Medicines Updates on Employee Share Purchase Plan Uptake

BeOne Medicines Aligns 2025 Results With Dual Hong Kong and U.S. Reporting Rules

BeOne Medicines Aligns 2025 Results With Dual Hong Kong and U.S. Reporting Rules

09988

00883

00467

00632

09903

09660

02865

On March 10, 2026, Hong Kong stocks collectively rose during the trading session, with the Hang Seng Index up 1.19% at 25,709.86 points, and the Hang Seng Tech Index approaching the 5,000-point mark. The internet content and retail sectors led the gains, with major stocks like Tencent Holdings, Alibaba, and JD.com significantly rising, boosting market risk appetite. Meanwhile, the oil and gas sector was pressured by weakening oil prices, with China National Offshore Oil Corporation falling over 2%. On the macro front, employment and foreign exchange remained stable, with funds focusing on the pace of domestic demand recovery

- As of March 10, 2026, Hong Kong stocks rose collectively, with the Hang Seng Index gaining 1.19% to 25,709.86 points amidst improved risk appetite, yet falling short of breaking through previous highs.  
- Key sectors included internet content, where Tencent increased by 3.10%, and retail, reflected by gains from Alibaba and JD.com, while oil and gas stocks fell sharply due to declining international prices.  
- Macroeconomic indicators showed stability in forex reserves and unemployment, prompting investor focus on retail sales and manufacturing for potential growth opportunities.

BABA-W

CNOOC

UNITEDENERGY GP

CHK OIL

ILUVATAR COREX

HORIZONROBOT-W

DRINDA

BABA 2x Long Daily ETF - GraniteShares

Hong Kong Stock Market Update | Hang Seng Index rises 1.19%, Tencent and Alibaba lead the market

JPBEONE@EC2610A(28521.HK)

JPBEONE@EC2610A Stock Performance Chart

BeOne Medicines Revamps Board and Committees Ahead of 2026 AGM

BeOne Medicines annual revenue is 38.2 billion: net profit 1.46 billion, Amgen and Baker are core shareholders

The Hang Seng Index rose 0.43% during the midday break, and the Hang Seng TECH Index increased by 0.17%

<![CDATA[Amgen’s Tarlatamab Approved in China ]]>

FOSUN PHARMA CFO Chen Zhanyu resigns, former BeOne Medicines executive Huang Zhi takes over